These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1731853)

  • 1. Cholesterol and triglyceride fatty acid synthesis in apolipoprotein E2-associated hyperlipidemia.
    Jones PJ; Dendy SM; Frohlich JJ; Leitch CA; Schoeller DA
    Arterioscler Thromb; 1992 Jan; 12(1):106-13. PubMed ID: 1731853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between apolipoprotein E phenotype and endogenous cholesterol synthesis as measured by deuterium uptake.
    Roe RP; Jones PJ; Frohlich JJ; Schoeller DA
    Cardiovasc Res; 1991 Mar; 25(3):249-55. PubMed ID: 2029714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lathosterol level in plasma is elevated in type III hyperlipoproteinemia, but not in non-type III subjects with apolipoprotein E2/2 phenotype, nor in type IIa or IIb hyperlipoproteinemia.
    Kempen HJ; Gevers Leuven JA; van der Voort HA; de Knijff P; Havekes L
    Metabolism; 1991 Mar; 40(3):231-5. PubMed ID: 2000034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. Evidence for a gene-gene interaction.
    Hopkins PN; Wu LL; Schumacher MC; Emi M; Hegele RM; Hunt SC; Lalouel JM; Williams RR
    Arterioscler Thromb; 1991; 11(5):1137-46. PubMed ID: 1680391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of apolipoprotein E polymorphism on plasma lipid and apolipoprotein levels, and clinical characteristics of type III hyperlipoproteinemia due to apolipoprotein E phenotype E2/2 in Japan.
    Kobori S; Nakamura N; Uzawa H; Shichiri M
    Atherosclerosis; 1988 Jan; 69(1):81-8. PubMed ID: 3355609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Independent effects of Apo E phenotype and plasma triglyceride on lipoprotein particle sizes in the fasting and postprandial states.
    Dart AM; Cooper B
    Arterioscler Thromb Vasc Biol; 1999 Oct; 19(10):2465-73. PubMed ID: 10521377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remnant-like lipoprotein particles in type 2 diabetic patients with apolipoprotein E3/3 and apolipoprotein E2 genotypes.
    Saito M; Eto M; Kaku K
    Metabolism; 2002 Aug; 51(8):964-9. PubMed ID: 12145767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postprandial vitamin A and squalene clearances and cholesterol synthesis off and on lovastatin treatment in type III hyperlipoproteinemia.
    Gylling H; Relas H; Miettinen TA
    Atherosclerosis; 1995 May; 115(1):17-26. PubMed ID: 7669084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tracing lipogenesis in humans using deuterated water.
    Jones PJ
    Can J Physiol Pharmacol; 1996 Jun; 74(6):755-60. PubMed ID: 8909788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum remnant lipoprotein cholesterol/triglyceride ratio as an index for screening familial type III hyperlipidaemia.
    Nakajima K; Daimon M; Kamiyama K; Takanashi K; Suzuki Y; Watanabe M; Kubono K; Saniabadi AR; Takashima S; Sakurabayashi I
    Ann Clin Biochem; 2007 Jul; 44(Pt 4):353-9. PubMed ID: 17663088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma cholesterol synthesis using deuterated water in humans: effect of short-term food restriction.
    Jones PJ; Scanu AM; Schoeller DA
    J Lab Clin Med; 1988 Jun; 111(6):627-33. PubMed ID: 3373108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein E2 (Lys146-->Gln) causes hypertriglyceridemia due to an apolipoprotein E variant-specific inhibition of lipolysis of very low density lipoproteins-triglycerides.
    de Beer F; van Dijk KW; Jong MC; van Vark LC; van der Zee A; Hofker MH; Fallaux FJ; Hoeben RC; Smelt AH; Havekes LM
    Arterioscler Thromb Vasc Biol; 2000 Jul; 20(7):1800-6. PubMed ID: 10894820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response of cholesterol synthesis to cholesterol feeding in men with different apolipoprotein E genotypes.
    Jones PJ; Main BF; Frohlich JJ
    Metabolism; 1993 Aug; 42(8):1065-71. PubMed ID: 8345812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein EBethesda: a new variant of apolipoprotein E associated with type III hyperlipoproteinemia.
    Gregg RE; Ghiselli G; Brewer HB
    J Clin Endocrinol Metab; 1983 Nov; 57(5):969-74. PubMed ID: 6578216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism of apolipoprotein B-100 and of triglyceride-rich lipoprotein particles in the absence of functional lipoprotein lipase.
    Pacy PJ; Mitropoulos KA; Venkatesan S; Watts GF; Reeves BE; Halliday D
    Atherosclerosis; 1993 Nov; 103(2):231-43. PubMed ID: 8292098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postprandial remnant-like lipoproteins in hypertriglyceridemia.
    Ooi TC; Cousins M; Ooi DS; Steiner G; Uffelman KD; Nakajima K; Simo IE
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3134-42. PubMed ID: 11443178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
    Kypreos KE; Li X; van Dijk KW; Havekes LM; Zannis VI
    Biochemistry; 2003 Aug; 42(33):9841-53. PubMed ID: 12924933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of dietary docosahexaenoic acid on plasma lipoproteins and tissue fatty acid composition in humans.
    Nelson GJ; Schmidt PC; Bartolini GL; Kelley DS; Kyle D
    Lipids; 1997 Nov; 32(11):1137-46. PubMed ID: 9397398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-HDL-cholesterol/apolipoprotein B ratio: a useful distinguishing feature in the screening for type III hyperlipoproteinemia.
    Murase T; Okubo M; Takeuchi I
    J Clin Lipidol; 2010; 4(2):99-104. PubMed ID: 21122636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triglyceride-rich lipoproteins of subjects heterozygous for apolipoprotein E2(Lys146-->Gln) are inefficiently converted to cholesterol-rich lipoproteins.
    Mulder M; van der Boom H; de Knijff P; Braam C; van den Maagdenberg A; Leuven JA; Havekes LM
    Atherosclerosis; 1994 Aug; 108(2):183-92. PubMed ID: 7980718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.